Read AB21® full scientific paper:
Scientific evidence of AB21®
4x blinded, single-center, randomized, placebo-controlled study. 300 patients with mild to moderate COVID-19 symptoms
Patients were randomized to take orally once a day probiotic AB21 or placebo, for 30 days
AB21 shortened -5 days median symptoms duration (p<0.001). SARS-CoV2 antibodies were significantly increased
Methodology
4x blinded
(patient, caregiver, investigator and outcomes assessors)
Single-center,
randomized, placebo-controlled clinical trial
Parallel arms
300 patients
one dose daily
Mild to moderate COVID-19
- With at least 1 COVID-19 symptom (cough, headache, fever, muscular pain, shortness of breath)
- Positive RT-qPCR
- Symptom onset less than 7 days before recruitment
- No need of oxygen therapy
18 to 60 year-old
(median age of 37)
Study design

and random
allocation
Main findings
AB21 full scientific presentation available only on demand

No Data Found
53%
Remission was defined as disappearance of symptoms and negative RT-qPCR. As primary study outcome, remission rate on day 30 was 53·1% (78 of 147) in the active group compared to 28·1% (41 of 146) in the placebo group (p<0·0001)
-5 days
Probiotic group had a median symptoms duration of 13 days, while in the placebo group it was 18 days. Probiotic effect on symptoms was robust to baseline imbalances

No Data Found

No Data Found
-2 to -5 days
Average duration of individual symptoms was significantly reduced in probiotic compared to placebo (ranging from p < 0.05 to p <0.001)
x2
Higher increase of SARS-CoV2-specific IgG in serum (p < 0·0001). Differences significant both on day 15 and day 30.

No Data Found

No Data Found
Higher increase of SARS-CoV2-specific IgM in serum (p < 0·0001). Differences significant both on day 15 and day 30.
Lung abnormalities were monitored via X-ray. Probiotic reduced overall scoring on days 15 and 30 vs placebo (both p < 0.001)

No Data Found

No Data Found
Significant reduction of viral load by probiotic compared to placebo (p < 0.001).
Evaluated in nasopharyngeal swabs
A post-hoc analysis identified an effect on Beta-Interferon levels, with a significant increase vs placebo on days 15 and 30 (p<0.001)


No Data Found
Interested in knowing more?
Recently, AB21® clinical trial results where presented at the 8th IHMC Congress. Fulfill the form below and you will recieve the recorded session. Only available for industry members and healthcare professionals.